Protagonist Therapeutics (NASDAQ:PTGX) Insider Arturo Md Molina Sells 2,718 Shares of Stock

Key Points

  • Insider Arturo Molina sold 2,718 shares for about $338,799, a 3.23% reduction in his holdings. The sale covered tax withholding obligations tied to vested equity awards.
  • Protagonist Therapeutics reported quarterly EPS of $3.07, beating the $2.50 consensus, and revenue of $274.41 million, above estimates of $238.49 million.
  • Analysts maintain a consensus Buy rating, with an average price target of $166.67.

Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Get Free Report) insider Arturo Molina sold 2,718 shares of the stock in a transaction dated Monday, November 16th. The shares were sold at an average price of $124.65, for a total transaction of $338,798.70. Following the sale, the insider directly owned 81,397 shares of the company's stock, valued at approximately $10,146,136.05. The trade was a 3.23% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Protagonist Therapeutics Stock Performance

NASDAQ:PTGX opened at $124.67 on Wednesday. Protagonist Therapeutics, Inc. has a fifty-two week low of $77.00 and a fifty-two week high of $160.81. The stock has a market capitalization of $8.14 billion, a P/E ratio of 26.41 and a beta of 1.21. The company's 50-day simple moving average is $139.45 and its 200-day simple moving average is $119.55.




Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last issued its quarterly earnings data on Thursday, November 5th. The company reported $3.07 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.50 by $0.57. The firm had revenue of $274.41 million for the quarter, compared to the consensus estimate of $238.49 million. Protagonist Therapeutics had a net margin of 62.04% and a return on equity of 42.83%. On average, research analysts forecast that Protagonist Therapeutics, Inc. will post 5.52 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the stock. Citigroup raised their target price on shares of Protagonist Therapeutics from $175.00 to $182.00 and gave the company a "buy" rating in a research note on Monday, August 31st. BMO Capital Markets lifted their price target on shares of Protagonist Therapeutics from $178.00 to $190.00 and gave the stock an "outperform" rating in a report on Tuesday, September 1st. Wall Street Zen downgraded Protagonist Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Sunday. Zacks Research raised Protagonist Therapeutics from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, October 14th. Finally, UBS Group reiterated a "buy" rating on shares of Protagonist Therapeutics in a report on Tuesday, November 3rd. One equities research analyst has rated the stock with a Strong Buy rating and sixteen have issued a Buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $166.67.

View Our Latest Stock Report on Protagonist Therapeutics

Institutional Investors Weigh In On Protagonist Therapeutics

Several institutional investors have recently added to or reduced their stakes in PTGX. Keating Financial Advisory Services Inc. acquired a new position in shares of Protagonist Therapeutics during the second quarter valued at about $30,000. Allworth Financial LP purchased a new position in shares of Protagonist Therapeutics in the 2nd quarter valued at approximately $31,000. Quantbot Technologies LP purchased a new position in shares of Protagonist Therapeutics in the 2nd quarter valued at approximately $42,000. Parallel Advisors LLC raised its position in shares of Protagonist Therapeutics by 205.9% in the 3rd quarter. Parallel Advisors LLC now owns 361 shares of the company's stock valued at $51,000 after purchasing an additional 243 shares during the last quarter. Finally, Harbor Investment Advisory LLC acquired a new stake in Protagonist Therapeutics in the 2nd quarter worth approximately $89,000. Institutional investors and hedge funds own 98.63% of the company's stock.

Protagonist Therapeutics Company Profile

(Get Free Report)

Protagonist Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops peptide-based medicines, primarily for inflammatory and blood disorders. Its research approach uses engineered peptides designed to act on specific biological targets. The company's programs include rusfertide, a hepcidin mimetic being developed for polycythemia vera, and icotrokinra, an oral interleukin-23 receptor antagonist being developed for immune-mediated diseases. Protagonist has entered into licensing and development collaborations for these programs with Takeda and Johnson & Johnson, respectively; they are investigational medicines, not approved treatments.

Further Reading

Insider Buying and Selling by Quarter for Protagonist Therapeutics (NASDAQ:PTGX)

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].

Insider Buying or Selling at Protagonist Therapeutics?
Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Protagonist Therapeutics and related companies.
Free Insider Buying and Selling Newsletter
Enter your email address below to receive InsiderTrades.com's daily insider buying and selling report.
From Our Partners

Most Read This Month

Recent Articles